Vietnam vehicle market grows 4% in May
Vietnam's new vehicle market expanded by 4% to 22,658 units in May 2025 from 21,767 units a year earlier, according to wholesale data released by the Vietnam Automotive Manufacturers Association (VAMA). The data do not include sales by Mercedes-Benz, Hyundai, Tesla, Nissan, domestic automaker VinFast, and several Chinese brands that have entered the market in the last two years.
VAMA's members reported slower sales growth last month, following a strong rebound over the last year from depressed levels. The latest government data show that GDP expanded by 5.9% year-on-year in the first quarter of 2025, moderating from 7.5% in the fourth quarter of 2024, underpinned by strong domestic consumption and exports.
In the first five months of 2025 the market expanded by 12% to 104,780 units from 93,653 units a year-earlier, according to VAMA data, with sales of passenger vehicles rising by 7% to 71,794 units while commercial vehicle deliveries surged by 23% to 32,986 units.
Truong Hai (Thaco) Group, the local assembler and distributor of several overseas brands and a major player in the commercial vehicle segment, reported a 14% sales rise to 33,806 units in this period. This includes a 48% jump in Thaco commercial vehicle sales to 10,050 units, and a 17% rise in Mazda sales to 11,803 units, while Kia sales declined by 9% to 10,116 units.
Toyota's sales surged by 34% to 23,061 units year-to-date, driven by strong Yaris Cross and Vios volumes, while Ford's sales rose by 22% to 17,533 units; Mitsubishi 12,130 units (+4%).; and Honda 9,710 units (+7%).
Domestic automaker VinFast announced separately that it delivered 56,187 battery electric vehicles (BEVs) to customers in Vietnam in the first five months of the year, with the VF3 and VF5 models accounting for around two-thirds of the total. Hyundai's passenger vehicle sales data for May were not available, but its local distributor Tan Chong International reported sales of 15,944 units in the first four months of the year.
The Vietnamese Ministry of Finance announced in March that it had extended the vehicle registration tax exemption for battery electric vehicles (BEVs) until the end of February 2027, extending it for an additional two years.
"Vietnam vehicle market grows 4% in May" was originally created and published by Just Auto, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
China Boosts Credit with $204B Bond Push--But Borrowing Stays Muted
China's credit growth picked up in Maybut the momentum came from Beijing, not the private sector. The People's Bank of China reported nearly 1.5 trillion yuan ($204 billion) in government bonds were sold last month, roughly 20% higher than a year ago. That marks the third time in 2025 bond sales have topped 1 trillion yuan in a single month. The surge helped lift total aggregate financing to 2.29 trillion yuan, an increase from 2 trillion yuan in May 2024. On the ground, though, the appetite for new borrowing looks subdued. Households took out just 54 billion yuan in new loans last month, bringing the year-to-date total to 572 billion yuanthe lowest since at least 2009. New loans from financial institutions also fell, landing at 620 billion yuan, well below last year's 945 billion yuan for the same period. This comes even after the PBOC announced sweeping monetary easing in early May, including across-the-board rate cuts and liquidity moves that could inject 2.1 trillion yuan into the economy. According to Bloomberg Economics' Eric Zhu, May's numbers suggest the government is delivering on its stimulus plans, but the response from households and businesses remains cautious. For global investors watching China's recovery story, the next leg of growth may depend on whether demand strengthens beyond public-sector activity. Companies with strong exposure to the Chinese consumer, including Tesla (NASDAQ:TSLA), could be watching for early signs of a turn in private-sector sentiment. This article first appeared on GuruFocus.
Yahoo
38 minutes ago
- Yahoo
AstraZeneca taps Chinese biotech in $5.2bn chronic disease research deal
AstraZeneca has joined the long list of big pharma companies enlisting the services of Chinese biotechs, signing a deal worth up to $5.2bn with CSPC Pharmaceuticals to research chronic disease drug candidates. Under the deal, AstraZeneca will pay an upfront fee of $110m, along with milestone payments of $1.62bn. CSPC are also in line to receive $3.6bn in sales milestone payments. AstraZeneca and CSPC will discover and develop pre-clinical candidates for multiple targets, which, according to the companies, will have the 'potential to treat diseases across chronic indications, including a pre-clinical small molecule oral therapy for immunological diseases'. CSPC will use its AI-powered drug discovery platform, which uses the technology to analyse the binding patterns of target proteins with existing compound molecules. The AI models work out targeted optimisation, advancing small molecules with the best developability. For any candidates identified via the research partnership, AstraZeneca will have the right to exercise options for exclusive licences to develop and commercialise candidates worldwide. AstraZeneca's executive vice president and biopharmaceuticals R&D head Sharon Barr said: 'This strategic research collaboration underscores our commitment to innovation to tackle chronic diseases, which impact over two billion people globally. 'Forming strong collaborations allows us to leverage our complementary scientific expertise to support the rapid discovery of high-quality novel therapeutic molecules to deliver the next-generation medicines.' The partnership marks the second time this year AstraZeneca has invested resources in China. In March 2025, the drugmaker revealed plans to infuse $2.5bn over the next five years in Beijing to establish an R&D hub. China is enjoying a fruitful alliance with Western big pharma companies, despite a frosty relationship with US President Trump's administration, mainly due to the BIOSECURE ACT, which is admittedly now in legislative limbo. Licensing deals between US and Chinese biopharma companies hit record highs last year, up 280% from 2020, according to analysis by GlobalData. Across big pharma, transactions rose 66% from $16.6bn in 2023 to $41.5bn in 2024, demonstrating that China is still the go-to place to discover pipeline candidates. For deals specific to US companies, the analysis found that total deal value rose from $15.7bn in 2023 to $21.3bn in 2024. GlobalData is the parent company of Pharmaceutical Technology. "AstraZeneca taps Chinese biotech in $5.2bn chronic disease research deal" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Oil prices surge, stocks tumble in the wake of Israel's strikes on Iran
Oil prices surged and stocks tumbled Friday in the wake of Israel's strikes on Iran's top military officials and nuclear sites. U.S. oil benchmark prices climbed roughly 7% to about $73 a barrel, the highest level since early April. Major stock indexes fell about 1%. U.S. government borrowing costs climbed. Tech stocks like Nvidia and Tesla moved lower, while shares in oil and defense-industry firms like Chevron, Lockheed Martin, and Palantir traded up. Gold prices also neared all-time highs, rising more than 1.5% to as much as $3,440 an ounce. The price of bitcoin fell more than 1% to less than $105,000. Israel launched strikes on Iran early Friday local time, a dramatic escalation of long-running tensions between the two countries. Israel officials have warned of a "lengthy operation," while President Donald Trump said there was "much more to come" from Israel and that Iran should make a deal. Iran has so far retaliated by launching drones toward Israel while also threatening U.S. assets in the region. The strikes add another chapter to what has already proven a turbulent year for markets. After a burst of investor optimism following Trump's inauguration in January, both stocks and bonds have been buffeted by uncertainty sparked by the chaos surrounding the president's tariff rollout. While stock indexes have overall recovered for a slight gain year to date, measures of daily market volatility remain elevated. And while spiking oil prices usually signal higher gasoline prices for consumers in the coming days and weeks, experts said there was no need to rush out to the pump. Even with the latest increases, oil prices remain below pandemic-era highs. "Higher gas prices are coming. But it will not be insane, and ultimately gas prices remain affordable vs income," Patrick De Haan, head of petroleum analysis at price tracker GasBuddy, said in a post on X. Higher oil prices can also stoke inflation. If that happens, it could complicate the Federal Reserve's calculations as it continues to weigh a weakening job market against fears of the price impact from Trump's tariffs. Before the strikes, stocks appeared to be heading for a winning week after the Trump administration signaled renewed interest in a rapprochement with China over trade concerns. The president said he planned on stabilizing import duties on Chinese goods at 55%, while those on U.S. goods into China would be set at 10%. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
